As the global economy recovers in 2021 and the supply of the industrial chain improves, the Peptide-Drug Conjugates market will undergo major changes. According to the latest research, the market size of the Peptide-Drug Conjugates industry in 2021 will increase by USD million compared to 2020, with a growth rate of %.
The global Peptide-Drug Conjugates industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also contains descriptions of key players, including key financial indicators and market competitive pressure analysis.
The report also assesses key opportunities in the market and outlines the factors that are and will drive the growth of the industry. Taking into account previous growth patterns, growth drivers, and current and future trends, we also forecast the overall growth of the global Peptide-Drug Conjugates market during the next few years. The global Peptide-Drug Conjugates market size will reach USD million in 2028, growing at a CAGR of % during the analysis period.
Highlights-Regions
The Peptide-Drug Conjugates market can be split based on product types, major applications, and important regions as follows:
North America
Europe
Asia Pacific
Latin America
Player list
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
Types list
Cell-penetrating Peptides (CPPs)
Cell-targeting Peptides (CTPs)
Application list
Carcinoma
Sarcoma
Melanoma
Lymphoma
Leukemia
Table of Content
1 Peptide-Drug Conjugates Market Scope Analysis Introduction
1.1 Peptide-Drug Conjugates Product Definition and Scope Introduction
1.2 Peptide-Drug Conjugates Market dynamics
1.3 Peptide-Drug Conjugates Market Segmentation
1.3.1 Peptide-Drug Conjugates Segment by Type
1.3.2 Peptide-Drug Conjugates Segment by Applications
1.4 Report Timeline
2 Methodology and Data Source
2.1 Methodology/Research Approach
2.1.1 Research Programs/Design
2.1.2 Market Size Estimation
2.1.3 Market Breakdown and Data Triangulation
2.2 Data Source
2.2.1 Secondary Sources
2.2.2 Primary Sources
2.2.3 Legal Disclaimer
3 Analysis of key market players
3.1 AstraZeneca
3.1.1 Business Overview
3.1.2 Peptide-Drug Conjugates Product Introduction
3.1.3 AstraZeneca Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
3.2 Bicycle Therapeutics
3.2.1 Business Overview
3.2.2 Peptide-Drug Conjugates Product Introduction
3.2.3 Bicycle Therapeutics Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
3.3 Cybrexa Therapeutics
3.3.1 Business Overview
3.3.2 Peptide-Drug Conjugates Product Introduction
3.3.3 Cybrexa Therapeutics Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
3.4 Esperance Pharmaceuticals
3.4.1 Business Overview
3.4.2 Peptide-Drug Conjugates Product Introduction
3.4.3 Esperance Pharmaceuticals Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
3.5 Oncopeptides
3.5.1 Business Overview
3.5.2 Peptide-Drug Conjugates Product Introduction
3.5.3 Oncopeptides Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
3.6 Pepgen Corporation
3.6.1 Business Overview
3.6.2 Peptide-Drug Conjugates Product Introduction
3.6.3 Pepgen Corporation Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
3.7 Soricimed Biopharma
3.7.1 Business Overview
3.7.2 Peptide-Drug Conjugates Product Introduction
3.7.3 Soricimed Biopharma Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
3.8 Theratechnologies
3.8.1 Business Overview
3.8.2 Peptide-Drug Conjugates Product Introduction
3.8.3 Theratechnologies Peptide-Drug Conjugates Sales, Price, Revenue, Gross Margin
4 Peptide-Drug Conjugates Historical and Forecast Market Size by Type
4.1 Peptide-Drug Conjugates Market Historical Size by Type (2017-2022)
4.2 Peptide-Drug Conjugates Market Forecast Size by Type (2023-2028)
5 Peptide-Drug Conjugates Historical and Forecast Market Size by Application
5.1 Peptide-Drug Conjugates Market Historical Size by Application (2017-2022)
5.2 Peptide-Drug Conjugates Market Forecast Size by Application (2023-2028)
6 Peptide-Drug Conjugates Historical and Forecast Market Size by Region
6.1 Peptide-Drug Conjugates Historical and Forecast Sales Market Size by Region
6.2 Peptide-Drug Conjugates Historical and Forecast Revenue Market Size by Region
6.3 Peptide-Drug Conjugates Historical and Forecast Market Size by Country
6.3.1 Peptide-Drug Conjugates Historical and Forecast Sales Market Size by Country (2017-2028)
6.3.1.1 United States Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.2 Canada Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.3 Germany Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.4 UK Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.5 France Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.6 Italy Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.7 Russia Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.5 China Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.6 Japan Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.7 Southeast Asia Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.8 Korea Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.9 India Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.10 Brazil Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.1.11 Mexico Peptide-Drug Conjugates Sales and Growth (2017-2028)
6.3.2 Peptide-Drug Conjugates Historical and Forecast Revenue Market Size by Country (2017-2028)
6.3.2.1 United States Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.2 Canada Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.3 Germany Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.4 UK Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.5 France Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.6 Italy Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.7 Russia Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.5 China Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.6 Japan Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.7 Southeast Asia Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.8 Korea Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.9 India Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.10 Brazil Peptide-Drug Conjugates Revenue and Growth (2017-2028)
6.3.2.11 Mexico Peptide-Drug Conjugates Revenue and Growth (2017-2028)
7 Peptide-Drug Conjugates Market Dynamics
7.1 Market Drivers
7.2 Market Restraints
7.3 Opportunity
7.4 Market Trends
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Peptide-Drug Conjugates Distributors List
8.3 Peptide-Drug Conjugates Customers
9 Research Findings and Conclusion
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
*If Applicable.
Links
[1] https://www.marketresearchreports.com/countries/north-america[2] https://www.marketresearchreports.com/countries/europe[3] https://www.marketresearchreports.com/countries/china[4] https://www.marketresearchreports.com/countries/japan[5] https://www.marketresearchreports.com/countries/global[6] https://www.marketresearchreports.com/pharmaceutical-manufacturing[7] https://www.marketresearchreports.com/healthcare[8] https://www.marketresearchreports.com/pharma-healthcare